The genus Bartonella contains >40 species, and an increasing number of these Bartonella species are being implicated in human disease. One such pathogen is Bartonella ancashensis, which was isolated in blood samples from 2 patients living in Caraz, Peru, during a clinical trial of treatment for bartonellosis. Three B. ancashensis strains were analyzed by using whole-genome restriction mapping and highthroughput pyrosequencing. Genome-wide comparative analysis of Bartonella species showed that B. ancashensis has features seen in modern and ancient lineages of Bartonella species and is more related to B. bacilliformis. The divergence between B. ancashensis and B. bacilliformis is much greater than what is seen between known Bartonella genetic lineages. In addition, B. ancashensis contains type IV secretion system proteins, which are not present in B. bacilliformis. Whole-genome analysis indicates that B. ancashensis might represent a distinct Bartonella lineage phylogenetically related to B. bacilliformis.
B
artonelloses are major emerging infectious bacterial diseases because of the high prevalence of chronic Bartonella infections in mammals and humans and their increasing risk for infection of immunocompromised populations (1) (2) (3) (4) . Bartonella species are present worldwide and are associated with several diseases, such as Carrion's disease, caused by B. bacilliformis; cat-scratch disease, caused by B. henselae; and trench fever, caused by B. quintana (2, (5) (6) (7) . B. henselae and B. quintana are also associated with chronic infections, such as bacillary angimatosis and endocarditis, and B. quintana chronic bacteremia is found in homeless populations worldwide (3, (8) (9) (10) (11) (12) .
In addition to these 3 major infectious pathogens, an increasing number of new Bartonella spp. have been identified in recent years as zoonotic pathogens transmitted by diverse arthropod vectors (1, 2, 7) . Currently, >40 official and candidate Bartonella species are listed in the Taxonomy Database of the National Center for Biotechnology Information (http://www.bacterio.net/Bartonella.html); 31 are recognized species. During their evolution, Bartonella lineages have adapted to a variety of hosts and developed virulence factors associated with a diverse set of disease signs and symptoms (13) (14) (15) .
Despite the high mortality rate for bartonellosis in Peru, studies on Bartonella pathogens are insufficient and mainly focused on B. bacilliformis (16) . We previously reported identification of non-bacilliformis Bartonella in Peru during a clinical treatment trial (17) (18) (19) . Using single-locus sequence typing, we identified 3 isolates (designated 20.00, 20.60, and 41.60) from 4 whole blood specimens collected from 2 patients (nos. 20 and 41) at day 0 or 60 during the clinical treatment trial in the Ancash region of Peru and found that these isolates had citrate synthase (gltA) gene sequences that diverged from that of B. bacilliformis reference strain KC583 (17) (18) (19) . Multilocus sequencing typing and microbiological analyses indicated these 3 isolates are members of a novel Bartonella species, subsequently name B. ancashensis (17) .
In this study, we performed genomic analyses of 3 non-bacilliformis Bartonella isolates obtained from patient blood samples (isolates 20.00, 20.60, and 41.60). Wholegenome analyses confirmed our previous identification of the isolates as a new species (B. ancashensis) (20) and identified unique genomic characteristics of B. ancashensis and differences between B. ancashensis and its closest relative (B. bacilliformis).
Methods

Ethics Statement
The human subject use protocol, including clinical specimen collection, and the consent procedure were approved in 2002 by the Institutional Review Boards of the Uniformed Services University of the Health Sciences (Bethesda, MD, USA); the Naval Medical Research Center Institutional Review Board (Bethesda, MD, USA); and the Universidad Peruana Cayetano Heredia (Lima, Peru). The trial details are available in the International Standard Randomized Controlled Trial Number registry (https://www.isrctn.com; trial no. ISRCTN16597283). Patients enrolled were 1-60 years of age, and written consent was obtained from the patient or the parent or guardian of the patient enrolled in the study.
Study Protocol
A clinical trial to compare rifampin, the standard drug for treatment of bartonellosis caused by chronic B. bacilliformis infection, with azithromycin, a possible alternative drug, was conducted in 2003 in the Caraz District of the Ancash region of Peru (Blazes DL, trial no. ISRCTN16597283). Patients with suspected chronic B. bacilliformis infection (verruga peruana) either came to the local hospital in Caraz or were identified by home visits. Patients (>1 year of age) with verruga peruana were randomly chosen to receive either a daily dose of rifampin (Pfizer, New York, NY, USA) for 14 days or 2 weekly doses of azithromycin (Pfizer) on days 0 and 7. For the patients who participated in the trial, survey data and medical records were collected on day 0 (baseline; time of presentation at the local hospital), and patients were then given the 2-week antimicrobial drug treatment. Clinical data was also collected on days 7, 14, 30, and 60.
In addition, peripheral blood specimens were collected from each patient on days 0, 7, 14, and 60 into tubes containing sodium citrate solution at the local hospital in Caraz and transported on ice to the clinical laboratory at the US Naval Medical Research Unit No. 6 (Lima, Peru) for blood cultures and analysis by PCR. Selected specimens, Bartonella isolates, and genomic DNA extracts were sent to the Naval Medical Research Center (Silver Spring, MD, USA) and the Walter Reed Army Institute of Research (Silver Spring, MD, USA) for additional investigations.
Blood specimens were cultured for >8 weeks as described (17) (18) (19) . Bartonella culture-positive specimens were confirmed to be Bartontella species by using microbiological observations and molecular assays. Nucleic acids were isolated from culture-positive blood samples and subjected to PCR amplification of a 338-bp fragment of the gltA gene. The PCR product was sequenced by using the Sanger method.
We aligned partial gltA gene sequences (homologous to nt 781-1137 of the B. bacilliformis KC583 gltA gene) and used them for phylogenetic analyses. Samples with gltA sequences that showed major differences (>85% divergence) from those of B. bacilliformis were cultured on brain heart infusion agar supplemented with 10% defibrinated sheep blood (BD Diagnostics, Glencoe, MD, USA) for 10-28 days at the Naval Medical Research Center.
For next-generation sequencing (NGS), genomic DNA was extracted from Bartonella isolates, randomly fragmented by using focused ultrasonication (S2 System; Covaris, Inc., Woburn, MA, USA), and used in rapid shotgun genomic DNA library preparation and pyrosequencing with the 454 GS FLX Titanium System (Roche 454 Life Sciences, Branford, CT, USA). For whole-genome restriction map (WGRM) analysis, Bartonella isolates were freshly grown on brain heart infusion agar with 10% sheep blood at 30°C in an atmosphere of 5% CO 2 for 10-14 days. High molecular weight DNA was isolated by using the (16) . ‡Values are 16S rRNA gene copy number/microliter (quantitative cycle threshold). §Primers 22RC-3F (5-TTCGGCTTAGCTTATCCGTTTCACAA-3) and 32RC-5R (5-CGTAAGAGCTTTGTGGCAAAATAGCAA-3) were used; the expected PCR amplicons size was 0.8 kb, which corresponds to nt 673839-674636 of B. ancashensis (GenBank accession no. CP010401).
Argus Sample Preparation Kit (OpGen Inc., Gaithersburg, MD, USA). DNA quality and quantity were assessed by using the Argus QCard Kit and mapped by using the Argus MapCard Kit and Argus Enzyme Kit-AflII with the Argus System (OpGen Inc.). Downstream analysis, clustering, and genome alignment was performed by using MapSolver version 3.2.4. (OpGen Inc.). We de novo assembled NGS data into sequence contigs by using GS Assembler software version 2.5.3 (Newbler; https://wikis.utexas.edu/display/bioiteam/GS+De+novo+ assembler) and then assembled the contigs to scaffolds with the WGRM as the physical reference. PCR amplification and open reading frame annotation were used to complete genome assembling. After we virtually digested the complete genome sequence with AflII, we aligned the in silico wholegenome restriction map with the WGRM to ensure the correct order and orientation of the final assemblies (21) .
We performed pairwise genome-wide comparative analysis by comparing homologous proteins from pairs of Bartonella species. Results are presented as density distribution curves for amino acid identity and as dot plots for pairwise amino acid identity for each homologous protein. Genes of interest were subjected to additional analysis, including gene cluster comparisons. For genome-wide phylogenetic analysis of Bartonella species, complete genome sequences or assembly contigs of whole genome sequences were aligned by using Mauve version 2.3.1 (22) to identify single nucleotide changes in conserved genomic regions. A total of 12,740 single-nucleotide polymorphisms were found in in 25.2 kb of sequence common to all 38 Bartonella strains. A phylogenetic tree was constructed by using the R phangorn package (23) . The initial tree was constructed by using the neighbor-joining algorithm and optimized by using the parsimony maximum-likelihood method. Tree stability was evaluated by using 100 bootstrap replicates.
Results
In the clinical trial testing the efficacy of rifampin and azithromycin for treatment of chronic bartonellosis, blood specimens from 72 of 127 patients were positive for Bartonella species by culture, and gltA gene sequencing indicated that these patients were infected with only B. bacilliformis; however, 2 patients (nos. 20 and 41) were infected with B. ancashensis (17) (18) (19) . DNA extracts from the 4 original whole blood specimens from these patients (20.00, 20.60, 41.00, and 41.60) were tested by using quantitative bacterial 16S rDNA PCR, standard bacterial 16S PCR, and B. ancashensis-specific PCR (Table 1) . Whole blood from patient 20 was PCR negative for bacteria on days 0 and 60. However, high levels of bacteremia were seen for whole blood specimens from days 0 and 60 for patient 41.
Although levels of bacteremia differed greatly, clinical signs and symptoms for both patients were indistinguishable from each another and from those for other patients with confirmed cases of chronic B. bacilliformis infection. In addition, our results confirm that B. ancashensis was isolated from whole blood specimens of patient 41 on day 60, but not on day 0. The evidence suggests emergence of a novel Bartonella species in Peru that can cause its own verruga peruana-like infection in humans or possibly co-infect humans in conjunction with B. bacilliformis. It is intriguing that the (Figure 1) .
The complete genome sequence of B. ancashensis strain 20.00 (GenBank accession no. NZ_CP010401) is circular (1,466,048 bp) and has a G + C content of 38.4%. These values are similar to those for the complete genome sequence of B. bacilliformis KC583 (NC_008783.1) (1,445,021 bp and a G + C content of 38.2%). The inverted region of the 20.00 genome (0.64 Mb) is flanked by two 507-bp repetitive sequences in an opposite orientation. The repetitive sequence is 97% identical to the gene for B. bacilliformis integrase (protein family HMM PF00589), a DNA breaking-rejoining enzyme that catalyzes DNA recombination.
We used whole-genome phylogenetic analyses to examine the evolutionary relatedness between B. ancashensis and 40 other Bartonella strains (Table 2; Figure 2 ). This analysis, based on 12,740 single-nucleotide polymorphisms in genomic sequences conserved across all species, showed that B. ancashensis isolate 20.00 is most closely related to B. bacilliformis, B. bovis, and B. melophagi. The degree of similarity between B. ancashensis and 15 other Bartonella species was further examined by assessing the pairwise similarity of homologous protein with the basic local alignment search tool score ratio method (25) (Figure 3 , panel Figure 3, panel B) . Most B. ancashensis genes identified by pan-genome analyses had homologs in >1 Bartonella species (Figure 3,  panel B ). Eight protein-coding genes in B. ancashensis and B. bacilliformis were not present in any other species. An additional 5 protein-coding genes were present in B. ancashensis, B. bacilliformis, and B. australis, but in no other known species. In contrast, there were 8 protein-coding genes in B. ancashensis and all 14 species, excluding B. bacilliformis, but including B. australis, which is considered the most divergent Bartonella species currently recognized. Another 129 B. ancashensis protein-coding genes have homologs in only a subset of the non-bacilliformis Bartonella (26) .
In 3 regions of the B. ancashensis genome, the similarity between B. bacilliformis and B. ancashensis proteins was lower than the average value (Figure 4) . Proteins in variable region 1 (genes 30-90) are homologous to nonbacilliformis species proteins, including phage proteins, such as HigA and HigB. Proteins encoded in variable region 2 (genes 180-240) are absent from B. bacilliformis. Among these proteins are those that have high similarity with Bartonella type IV secretion system proteins, which are hypothetical gene products that have moderate identity with proteins from other non-bacilliformis species, and novel hypothetical proteins. Variable region 3 (genes 620-704) contains loci encoding hypothetical proteins not seen in other species and several toxin proteins that are not found in B. bacilliformis, including the RelE/StbE replicon stabilization toxin, the RelB/StbD replicon stabilization protein, and the HigB toxin protein.
Analysis identified 2 characteristic features of B. ancashensis: type IV secretion complex (VirB2) proteins, which are not found in B. bacilliformis; and flagella proteins, which are not found in Bartonella species in lineage 4, including human pathogens B. quintana and B. henselae (15, 27, 28 inversion, and this rearrangement results in 1 gene (FliJ) required for production of flagella arranged in a reversed orientation and separated from the other genes of the main flagellar gene cluster. In isolate 20.00, FliJ is ≈600 kb from the flagellar gene cluster; in isolates 20.60 and 41.60, FliJ is ≈100 kb from this cluster ( Figure 5) . A Leptospira species virulence attenuation study identified a group of paralogous virulence modulated (VM) genes, which are believed to play a role in human pathogenesis caused by Leptospira interrogans (29) . Subsequent comparative genomic analysis showed that VM proteins are present in other bacterial pathogens, including B. bacilliformis and B. australis; B. ancashensis encodes 5 VM proteins ( Figure 6 ). In contrast, no homologs of VM proteins were found by a basic local alignment search tool search in any other recognized Bartonella species. As seen for the VM proteins of Leptospira species, VM protein genes in these 3 Bartonella species were scattered throughout their genomes, and the number of VM proteins was different for each species. genes, which are believed to be essential for erythrocyte invasion, the main route of pathogenesis caused by B. bacilliformis (33) . In contrast, human pathogens B. quintana and B. henselae do not produce flagella, and hostspecific pathogenicity is believed to be linked to the type IV secretion system (T4SS) gene clusters VirB and Trw (27, 28, 33, 34) . B. ancashensis and 2 other pathogens (B. clarridgeiae and B. rochalimae) have flagellar and VirB T4SS gene clusters (15, 26, 27) . Whole-genome analysis of 3 B. ancashensis isolates showed that isolate 20.00 differs from the other 2 isolates by a large genomic region inversion. Future comparative analysis of gene expression profiles in these strains will show whether this genomic inversion alters the regulation of flagellar genes, as well as other virulence factors within or adjacent to the inverted region.
Moreover, it will be useful to investigate whether the genomic inversion (isolate 20.00 vs. 20.60) is related to administration of antimicrobial drugs to infected patients because isolates 20.60 and 41.60 were obtained from patients after they received antimicrobial drugs and cleared any clinical signs or symptoms of bartonellosis because infection persisted 60 days after enrollment in the study and administration of antimicrobial drugs. Furthermore, these isolates were previously tested for their in vitro susceptibility to rifampin and azithromycin and both were found to be susceptible (17) . However, in vitro antimicrobial drug susceptibility testing for Bartonella spp. has been largely limited in its clinical utility. However, B. ancashensis might be capable of producing chronic asymptomatic infections that could be caused by its unique genomic characteristics.
The VM genes belong to a family of homologous virulence-related genes originally identified in L. interrogans and modulate the pathogenesis of L. interrogans in humans (29) . These genes in B. bacilliformis, B. australis, and B. ancashensis, but not in other Bartonella spp., the further comparative analysis and functional studies on these VM proteins and the large number of other hypothetical proteins in Bartonella spp. will shed light on the pathogenesis mechanisms of bartonellosis, which are so far largely unknown.
Intensified tropical disease surveillance and advances in scientific methods led to an increasing number of new Bartonella species being identified in recent years (30, 35) . These studies identified 1 major phylogenetic lineage of the genus Bartonella. Our study and other genomic studies demonstrated that B. bacilliformis, which was historically regarded as the ancestral Bartonella spp., probably diverged from other species in the distant past and evolved as a species uniquely adapted to the human host because no small mammals have been implicated as reservoir hosts for B. bacilliformis (15, 26, 27, 36) . Although B. ancashensis is a novel species most closely related to B. bacilliformis, it has a nucleotide divergence of ≈20% when compared with B. bacilliformis for conserved genomic regions, which is exceedingly high and comparable with distances among proposed Bartonella lineages (15, 26) . Therefore, it is rational to designate B. ancashensis as an independent lineage parallel to the B. bacilliformis lineage. Our study provided evidence that there might be more Bartonella species and subspecies in regions of South America.
Bartonellosis has affected humans for hundreds to thousands of years, remains endemic to several areas, and continues to cause sporadic outbreaks in many regions. Identification of a novel Bartonella species in this study not only provided long-awaited evidence of species diversity in areas to which B. bacilliformis is endemic but also indicates the need for acquisition of sufficient genomic data, which will enable pathogenomics studies. Such studies will make essential contribution to a comprehensive understanding and effective control of bartonelloses.
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